DIGITAL EDITION

ARCHIVES

Category: Proceedings

Special Challenges in Pediatric Drug Development: First of Three Sets of Expanded Proceedings from the ISCTM Autumn Conference on Pediatric Drug Development

by Philip D. Harvey, PhD; Joan Busner, PhD; Gahan Pandina, PhD; H. Gerry Taylor, PhD; Meg Grabb, PhD; and Joohi Jimenez-Shahed, MD Dr. Harvey is with Department of Psychiatry, University

Implications of Pediatric Initiatives on CNS Drug Development for All Ages—2020 and Beyond: Second of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development

by Gahan Pandina, PhD; Joan Busner, PhD; Joseph P. Horrigan, MD; Christine McSherry, RN, BSN; Alison Bateman-House, MA, MPH, PhD; Luca Pani, MD; and Judith Kando, PharmD, BCPP Dr. Pandina

Patient Centricity: Design and Conduct of Clinical Trials in Orphan Diseases: Third of Three Sets of Expanded Proceedings from the 2020 ISCTM Autumn Conference on Pediatric Drug Development

by Joan Busner, PhD; Gahan Pandina, PhD; Simon Day, PhD; Atul Mahableshwarkar, MD; Lucas Kempf, MD; Maria Sheean, MD; and Judith Dunn, PhD Dr. Busner is with Signant Health in

Outcomes Assessment in Clinical Trials of Alzheimer’s Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs

by Holly Posner, MD, MS; Rosie Curiel, PsyD; Chris Edgar, PhD; Suzanne Hendrix, PhD; Enchi Liu, PhD; David A. Loewenstein, PhD; Glenn Morrison, MSc, PhD; Leslie Shinobu, PhD; Keith Wesnes,

CNS Summit 2016 Abstracts of Poster Presentations

Innov Clin Neurosci. 2017;14(1–2)3–23. A MESSAGE FROM THE EDITOR Dear Colleagues: Welcome to the annual CNS Summit Abstracts of Poster Presentations supplement to Innovations in Clinical Neuroscience. We are pleased

Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders

by the CNS SUMMIT DATA QUALITY MONITORING WORKGROUP CORE MEMBERS—David Daniel, MD; Amir Kalali, MD; Mark West; David Walling, PhD; Dana Hilt, MD; Nina Engelhardt, PhD; Larry Alphs, MD, PhD;

Translational and Early Phase Strategies for Treatment Development: Report of ISCTM Autumn 2013 Symposium

by Jared W. Young, PhD; William Z. Potter, MD, PhD; Steve Riley, PharmD, PhD; Geert J. Groeneveld, MD, PhD; Bruce J. Kinon, MD; Mike F. Egan, MD; and Douglas E.

How Can Registries Contribute to the Development and Evaluation of CNS Therapeutics?

by Joanne B. Severe, MS, and Annette Stemhagen, DrPH, FISPE Ms. Severe is a research consultant in Rockville, Maryland, and Dr. Stemhagen is with United Biosource Corp. in Bethesda, Maryland.